NCT05238220View on ClinicalTrials.gov

Utilization of the Viracor® Assay for Valganciclovir Prophylaxis in CMV High Risk Kidney Transplant Recipients

CompletedOBSERVATIONAL
Enrollment

37

Participants

Timeline

Start Date

January 4, 2021

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions
Kidney Transplant; Complications
Interventions
DRUG

Valganciclovir

continuation of valganciclovir prophylaxis up to 12 months with absence of demonstrated anti-CMV immunity

Trial Locations (1)

30309

Piedmont Atlanta Hospital, Atlanta

Sponsors
All Listed Sponsors
collaborator

ViraCor Laboratories

INDUSTRY

lead

Piedmont Healthcare

OTHER